FindTrial
Sign In

Rituximab (Mabthera) in metastatic melanoma

Rituximab (Mabthera) in metastatic melanoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005125-30-AT
Enrollment
Unknown
Registered
2008-10-20
Start date
2008-11-20
Completion date
Unknown
Last updated
2012-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic melanoma patients, clinical stage IIIc/IV ( AJCC2002), disease free

Interventions

Trade Name: Mabthera Product Name: MabThera Product Code: EU/1/98/067/002 Pharmaceutical Form: Intravenous infusion

Sponsors

Medizinische Universität Wien, Univ.Klinik für Dermatologie, Abteilung für Immundermatologie
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: male/female melanoma patients >18 years stage IIIc/IV disease free negative pregnancy test ECOG status=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: other tumors ( except basal cell Ca and squamous cell Ca) mucosal and uveal melanomas chronic infectious diseases autoimmune diseases or/ and immunosupressive therapy

Design outcomes

Primary

MeasureTime frame
Main Objective: time to progression overall survival;Secondary Objective: quality of life;Primary end point(s): 15 Patients 2 years period tumor progression—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026